Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

Summary

Roche is licensing an early-stage non-incretin obesity drug from Hanmi Pharm for $190 million upfront with potential total deal value of up to $2.3 billion, continuing Roche's strategy of building its obesity portfolio.